Navigation Links
Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
Date:6/28/2009

CHIPPENHAM, England and TOKYO, June 29 /PRNewswire/ --

- Study Triggers $7.5m Milestones for Both Companies

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of activity. The study has now appeared on clinicaltrials.gov and will be recruiting in the next few weeks when the first patient first visit will trigger a $7.5 million milestone payment to both Sosei and Vectura.

The trial is a randomised, double-blind, placebo-controlled, parallel-group design, including an open-label tiotropium bromide arm, and will assess efficacy, safety and tolerability of NVA237 in patients with COPD. It will include approximately 1000 patients with moderate to severe COPD from study centres across the USA, Europe and other territories. Each patient will be randomised to receive a once-daily dose of placebo, tiotropium bromide or 50microg of NVA237 for a 52-week period. The primary endpoint of the study will be the change from baseline in FEV1 (forced expiratory volume in one second) over 12 weeks of treatment. A number of secondary endpoints will also be evaluated.

NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. Novartis intends to launch NVA237 as a once-daily monotherapy for COPD and also in combination with Novartis' investigational once-daily, long-acting beta2-agonist (LABA) indacaterol (QAB149), which was filed for approval with the regulatory authorities as a monotherapy treatment for COPD at the end of 2008. The combination of NVA237 and indacaterol is known as QVA149. NDA submissions
'/>"/>

SOURCE Sosei Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...N,Nov.23/PRNewswire-FirstCall/--AMICAS,Inc.(Nasdaq...utions,todayannouncedthatitwillhighlightitsenterpr...SocietyofNorthAmerica(RSNA)annualmeetingfromNovemb...Hallinbooth#7124. ,, (Logo: http://www.newscom....nthenationalconversationabouthealthcarereform,ther...
(Date:11/23/2009)...v.23/PRNewswire/--BridgePointMedicalannouncedtoday...oritscoronaryandperipheralChronicTotalOcclusion(CT...singCatheterandtheStingray®CTORe-EntrySystem....tersthataredesignedtonavigatehighlydiseasedarterie...yandstenting. ,, TheNationalHeart,LungandBloodI...
(Date:11/23/2009)....,Nov.23/PRNewswire-FirstCall/-- CumberlandPharmac...p-lineresultsfromastudyevaluatingthesafetyandeffic...inhospitalizedburnpatients. ,, Statisticalsigni...everinburnpatientsoverthefirst24hoursoftreatment.T...rddegreeburnscoveringmorethan10percenttotalbodysur...
Breaking Medicine Technology:AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 2AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 3BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 3VA Chiefs Vow to The American Legion 3A We Will End Vet Homelessness 55343 1VA Chiefs Vow to The American Legion 3A We Will End Vet Homelessness 55343 2Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 1Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 2Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 3CorVel Announces Expansion to Share Buyback Program 55339 1CorVel Announces Expansion to Share Buyback Program 55339 2CorVel Announces Expansion to Share Buyback Program 55339 3
...ARD, Calif., March 24 Anthera Pharmaceuticals, In...eloping anti-inflammatory drugs, announced today t...cacy data from the first cohort of 30 patients, an...as recommended that Anthera,s Phase II clinical tr... M odulation of P hospholipase in A cute C hes ...
...4 The AXA Research Fund closed out its first year...nted more than Euro 13 million to various European...nd is to promote the understanding and prevention ...edge scientific research. The AXA Research Fund ha...rs, making it a major initiative in the realm of s...
Other Medicine Technology:Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 3First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3
(Date:11/24/2009)... Developed by Opticom Data Research, Float...amination of the eye. , N...oatScope is a new hand-held device for self-examin...ous ocular health conditions such as floaters and ...e functioning of the iris., , , FloatScope uses a...
(Date:11/23/2009)...m the University of Michigan determined that only ... with hepatitis C virus (HCV) infection received a... rates appear to be declining, in part because onl... this disturbing trend continues, by 2030 less tha...vented by antiviral therapy. This study, the firs...
(Date:11/23/2009)...N,Nov.23/PRNewswire/--TheLupusFoundationofAmericaG...ofsuccessprovidingfreeday-to-dayeducation,advicean...liesinthegreaterD.C.area.LFAGW,s35thAnniversaryLun....m.atB.Smith,s,50MassachusettsAve.,N.E.,Washington...lableat$100each.Tablesponsoropportunitiesare$1,500...
(Date:11/23/2009)... After suffering from women,s hair loss fo...ing back and she,s sharing her progress and the se...men through the release of her video diaries which...d during her treatment. , ...oss sufferer Zsanett Siklosi has released the vid...
(Date:11/23/2009)...retaryEncouragesUseofPAPreferredProductsinHolidayM...wire/--ToensurethatyourfamilyhasasafeThanksgivingm...ngisurgingresidentstofollowafewbasicfoodsafetystep...ollowingandunderstandingproperfoodhandlingandprepa...nksgivingdinnerissafetoeat,"saidRedding."Ignoringt...
Breaking Medicine News(10 mins):Health News:FloatScope - A New Device for Self-Viewing Eye Floaters 2Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Washington Lupus Chapter Celebrates 35th Anniversary on December 5 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Pennsylvania Agriculture Department Encourages Proper Food Handling, Offers Safety Tips for Thanksgiving 2
...g suggests complaint of a ,racing mind, is not jus...althDay News) -- Adults with primary insomnia have...more difficult for their brains to settle down for...t slows overall activity in many brain areas, acco...
...TION OF 75-PATIENT STUDY ON DIABETIC FOOT ULCERS, ...C Bulletin Board: DSCI) announced today the first ...Phase II study of its drug candidate, DSC127.,Enro...onths. Currently, 4 US facilities have signed on a...
... Minn., Nov. 3 Blue Cross and Blue Shield of,Minn... vice president and,chief information officer for ...on the board,s human resources and finance and bus...the business conduct,committee and the Tartan lead...
...his release is available in German . , SARS, a...ons are becoming increasingly frequent. And we sti...esponsible. One of the most dangerous classes of v...ile virus (WNV), which was first identified in Uga...
...AN FRANCISCO (November 3, 2008) New clinical data...onal protease inhibitor (PI) being developed by Ti...C virus (HCV) infection. Tibotec will present find...ciation for the Study of Liver Disease,s (AASLD) L...
...rvey from Sambucol(R) Black Elderberry immune boos... feels vulnerable and why; shows that,one-in-ten U.../weather,changes, NOTTINGHAM, England, Nov. 3 Mo...o a new survey,conducted for Sambucol(R) Black Eld...
Other Medicine News:Health News:Primary Insomnia Tied to Brain Neurochemical Imbalance 2Health News:Derma Sciences Enrolls First Patient in DSC127 Phase II Study 2Health News:Derma Sciences Enrolls First Patient in DSC127 Phase II Study 3Health News:Derma Sciences Enrolls First Patient in DSC127 Phase II Study 4Health News:Derma Sciences Enrolls First Patient in DSC127 Phase II Study 5Health News:Cargill Executive Joins Blue Cross Board of Trustees 2Health News:Therapeutic vaccines 2Health News:Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment 2Health News:Younger People, Not Seniors, Getting More Colds and Feeling Run Down 2
Misty Infant Custom Nebulizers
...esia and Respiratory Products, ,Westmed designs, ...devices for Anesthesia and Respiratory professiona...cts that enhance the clinician's ability to delive...n to the bottom line. , ,Our web site is designed...
...esia and Respiratory Products, ,Westmed designs, ...devices for Anesthesia and Respiratory professiona...cts that enhance the clinician's ability to delive...n to the bottom line. , ,Our web site is designed...
...PRONEB® ULTRA compressor. This high output com...ering more medication to the patient's lungs. When...AR® Reusable Nebulizer, the particle size of m...ion into the lungs. With less medication wasted, t...
Medicine Products: